Loading quotes...
Forecast
The analysts' average price target is €6.89 (+8.85%). The median is €6.72 (+6.16%).
| Buy |
0 |
| Hold |
8 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.49m | 144.76% |
| Gross profit | 1.3m | 212.56% |
| Net profit | -28.5m | 21.13% |
| EBITDA | -38.49m | 66.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.44bn |
Number of shares | 370.86m |
52-week high/low | €6.67 - €2.92 |
| Dividends | No |
Beta | 1.55 |
P/E ratio | -2.53 |
PEG ratio | 0.01 |
P/B ratio | 15.03 |
P/S ratio | 609.40 |
Company profile
| Name | Atai Beckley NV |
| CEO | Srinivas G. Rao |
| Headquarters | New York,
ny USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 99 |
